Shoulder Innovations (SI) 2026 CG Musculoskeletal Conference summary
Event summary combining transcript, slides, and related documents.
2026 CG Musculoskeletal Conference summary
4 Mar, 2026Market overview and growth
Shoulder arthroplasty is a sub-$3 billion market growing at over 10% annually, with the reverse shoulder style now representing over 70% of procedures worldwide.
Trailing twelve-month revenue reached $42 million at the end of Q3 2025, reflecting a 55% CAGR over the prior eight quarters and a 76% gross margin.
Outpatient procedures, especially in Ambulatory Surgery Centers, are rapidly increasing, now accounting for over 30% of procedures after a positive CMS payment decision in January 2024.
Growth is driven by high-volume surgeons, with 1,800 targeted specialists and 95% of revenue from core and contender customers growing over 50% year-over-year.
Expansion into international markets is planned for the coming quarters, with all current revenue from the U.S.
Technology and innovation
Proprietary InSet glenoid implant addresses glenoid loosening, reducing rocking horse motion by 87% and achieving up to 100% survivorship at nine years.
AI-enabled ProVoyance 3D preoperative planning platform is fully adopted by surgeons and central to product deployment and customer engagement.
Two Tray platform system simplifies surgical workflow, reduces costs, and is tailored for Ambulatory Surgery Centers.
Recent product introductions include the I-135 platform for fracture indications and N22 Glenospheres for metal hypersensitivity, both in limited user release.
Partnership with Interventional Systems enables a portable, robotics-as-a-service model, aiming for time-neutral, capital-light deployment in operating rooms.
Commercial strategy and future outlook
Unique commercial model combines a 1099 indirect distribution network with a focused W-2 commercial and customer experience team.
Focused on high-volume surgeons, with a man-demand approach to relationship building and product adoption.
New products are positioned at higher price points, supporting price stabilization in a typically deflationary orthopedic market.
Robotics solution is not yet in market but has generated significant interest and positive perception among surgeons.
Future growth drivers include international expansion and potential entry into additional soft tissue indications.
Latest events from Shoulder Innovations
- Q4 revenue up 65% and 2026 guidance targets 31–37% growth, driven by innovation and ASC momentum.SI
Q4 202510 Mar 2026 - Innovative implants and AI-driven planning fuel rapid growth and high margins in shoulder arthroplasty.SI
Investor presentation10 Mar 2026 - Disruptive InSet Glenoid and AI-driven platform fuel rapid growth in shoulder arthroplasty.SI
Investor presentation3 Mar 2026 - AI-driven planning and streamlined implants drive growth as ASC adoption accelerates.SI
Jefferies London Healthcare Conference 20253 Feb 2026 - 33% Q2 growth fueled by efficient two-tray system, ASC focus, and commercial scaling.SI
Morgan Stanley 23rd Annual Global Healthcare Conference31 Dec 2025 - Portable robotics and surgeon-focused innovation fuel rapid growth and strong margins.SI
Piper Sandler 37th Annual Healthcare Conference13 Dec 2025 - IPO seeks $88M to scale shoulder implant business, fund R&D, and expand in a competitive market.SI
Registration Filing29 Nov 2025 - IPO aims to fund growth for a fast-growing, loss-making shoulder implant innovator.SI
Registration Filing29 Nov 2025 - Offering 5M shares at $19–$21 to fund growth in the $1.7B U.S. shoulder arthroplasty market.SI
Registration Filing29 Nov 2025